Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 4;33(1):55-60.
doi: 10.4103/tcmj.tcmj_31_20. eCollection 2021 Jan-Mar.

Androgen deprivation therapy and the risk of subsequent keratitis

Dai-Wei Liu  1   2 , Ren-Jun Hsu  1   2 , Sheng-Yao Huang  1 , Yen-Hsiang Liao  1 , Chen-Ta Wu  1 , Wen-Lin Hsu  1   2
Affiliations
Review

Androgen deprivation therapy and the risk of subsequent keratitis

Dai-Wei Liu et al. Tzu Chi Med J. .

Abstract

Objectives: The objective of the study was to determine the risk of subsequent keratitis in prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT).

Materials and methods: Three thousand three hundred and nine patients with PCa were identified using data from Taiwan's National Health Insurance Research Database for 2001 through 2013. Among those patients, 856 treated with ADT comprised the study group, while 856 non-ADT-treated patients matched with 1:1 propensity-score-matched analysis comprised the control group. The demographic characteristics and comorbidities of all the patients were analyzed, and Cox proportional hazards regression was utilized to determine the hazard ratios (HRs) for subsequent keratitis.

Results: A total of 157 (9.2%) patients had newly diagnosed keratitis. Compared to the non-ADT-treated patients, the ADT-treated patients had a reduced risk of subsequent keratitis, with an adjusted HR of 0.38 (95% confidence interval: 0.27-0.55; P < 0.001).

Conclusion: ADT treatment apparently decreased the risk of subsequent keratitis in the investigated PCa patients, but the clinical significance of this finding should be further assessed in additional studies.

Keywords: Androgen deprivation therapy; Keratitis; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the study cohort selection. ADT: Androgen deprivation therapy
Figure 2
Figure 2
Kaplan–Meier curves indicating the cumulative rates of keratitis in patients treated with ADT and patients not treated with ADT and in the propensity score-matched cohort. ADT: Androgen deprivation therapy
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40. - PubMed
    1. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93:2042–9. - PubMed
    1. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Cardiovascular and metabolic complications during androgen deprivation: Exercise as a potential countermeasure. Prostate Cancer Prostatic Dis. 2009;12:233–40. - PubMed
    1. Wu CT, Yang YH, Chen PC, Chen MF, Chen WC. Androgen deprivation increases the risk of fracture in prostate cancer patients: A population-based study in Chinese patients. Osteoporos Int. 2015;26:2281–90. - PubMed

LinkOut - more resources